HC Wainwright Issues Optimistic Outlook for ACXP Earnings

Posted by Francis Steltz on Aug 18th, 2026

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Free Report) – HC Wainwright increased their Q3 2026 EPS estimates for Acurx Pharmaceuticals in a research note issued on Friday, August 14th. HC Wainwright analyst M. Keller now forecasts that the company will post earnings per share of ($0.45) for the quarter, up from their prior estimate of ($0.48). The consensus estimate for Acurx Pharmaceuticals’ current full-year earnings is ($1.94) per share. HC Wainwright also issued estimates for Acurx Pharmaceuticals’ Q4 2026 earnings at ($0.47) EPS, FY2026 earnings at ($2.00) EPS and FY2027 earnings at ($1.60) EPS.

Acurx Pharmaceuticals (NASDAQ:ACXP – Get Free Report) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.15).

ACXP has been the topic of several other reports. Wall Street Zen upgraded shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $31.00.

Check Out Our Latest Analysis on ACXP

Acurx Pharmaceuticals Stock Up 18.3%

Shares of NASDAQ:ACXP opened at $1.65 on Tuesday. Acurx Pharmaceuticals has a 52 week low of $1.31 and a 52 week high of $8.34. The stock has a market capitalization of $7.09 million, a P/E ratio of -0.61 and a beta of -2.03. The firm has a fifty day simple moving average of $1.52 and a two-hundred day simple moving average of $2.19.

Institutional Trading of Acurx Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Acurx Pharmaceuticals during the fourth quarter worth $27,000. Geode Capital Management LLC purchased a new stake in shares of Acurx Pharmaceuticals in the fourth quarter valued at $31,000. Millennium Management LLC purchased a new stake in shares of Acurx Pharmaceuticals in the fourth quarter valued at $103,000. Finally, Armistice Capital LLC bought a new stake in shares of Acurx Pharmaceuticals in the 2nd quarter worth about $551,000. 11.53% of the stock is currently owned by institutional investors.

About Acurx Pharmaceuticals

(Get Free Report)

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel anti‐infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).